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Abstract: Evidence available from nutritional epidemiology has indicated an inverse 
association between regular consumption of fruits and vegetables and the risk of developing 
certain types of cancer. In turn, preclinical studies have attributed the health-promoting 
effects of plant foods to some groups of phytochemicals, by virtue of their many biological 
activities. In this survey, we briefly examine the chemopreventive potential of flavonoids 
and flavonoid-rich foods in human oral carcinogenesis. Despite the paucity of data from 
clinical trials and epidemiological studies, in comparison to in vitro/in vivo investigations, 
a high level of evidence has been reported for epigallocatechin gallate (EGCG) and 
anthocyanins. These flavonoids, abundant in green tea and black raspberries, respectively, 
represent promising chemopreventive agents in human oral cancer. 
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1. Introduction 
Dietary habits rich in fruits, vegetables, legumes and whole cereals have been significantly 
correlated to a reduced risk of chronic degenerative disorders, particularly cardiovascular diseases and 
certain types of cancer [1,2]. Health-promoting effects of plant foods have been ascribed to their 
content in secondary metabolites. These phytochemicals, by virtue of their biological activities, 
possess different molecular and biochemical targets both in healthy and diseased cells. Antioxidant, 
anti-inflammatory, antimicrobial, pro/anti-apoptotic and vasodilating activities are only some of the 
properties of plant natural products responsible for their anticancer, cardio- and neuroprotective effects [3]. 
Plant tissues and, consequently, plant foods contain hundreds of bioactive secondary metabolites, 
including phenylpropanoids, isoprenoids and alkaloids [4]. Among these, phenylpropanoids have been 
particularly investigated in the two last decades, in order to ascertain health benefits attributed to diets 
rich in these metabolites. Only plants, including algae and some microorganisms, are able to synthesize 
phenylpropanoids from the free aromatic amino acids phenylalanine or tyrosine. The key enzyme in 
their biosynthesis is phenylalanine ammonia lyase, responsible for deamination of Phe, and, hence, in 
contrast to alkaloids, phenylpropanoids are ternary products, containing C, H and O. Hydroxybenzoates, 
hydroxycinnamates, coumarins, lignans, lignin and polyphenols are the main groups of 
phenylpropanoids. Therefore, the term polyphenols is not a synonymous of phenylpropanoids, but it 
refers to a vast group phenylalanine derivatives, in turn divided into flavonoids, stilbenes (including 
resveratrol) and proanthocyanidins (or condensed tannins) [5]. 
The flavonoid basic chemical structure is the flavan nucleus, a skeleton consisting of 15 carbon 
atoms arranged in three rings (C6–C3–C6): two aromatic rings (A and B) connected by a  
three-carbon-atom heterocyclic ring, an oxygen-containing pyran ring (C). The main classes of 
flavonoids (flavonols, flavanols, flavones, flavanones, isoflavones and anthocyanidins) differ in the 
level of oxidation and saturation of the C ring, while individual compounds within a class vary in the 
substitution pattern of the A and B rings (Figure 1). 
Flavonols mainly include kaempferol, quercetin and myricetin aglycones (not bound to a 
carbohydrate moiety), whereas flavan-3-ols (or flavanols) provide catechin epimers [(+)-catechin and  
(−)-epicatechin], the monomeric units for proanthocyanidin biosynthesis. Flavanones are typical of 
citrus fruits (genus Citrus), mainly represented by aglycones hesperetin and naringenin, whereas 
apigenin and luteolin are widely diffused flavones. Isoflavones, a group of phytoestrogens which 
includes soy genistein and daidzein, are important constituents of the Fabaceae family, with the B ring 
in position 3 instead of 2. Anthocyanidins are the most abundant pigments in the plant tegumental 
tissues. Their conjugated derivatives, anthocyanins, mainly bound to sugars (glycones), 
hydroxycinnamates or organic acids, are water-soluble pigments conferring blue, dark blue, violet,  
red and purple hues to flowers, fruits and other plant organs. Anthocyanins are structurally based  
on six aglycones/anthocyanidins––malvidin, cyanidin, delphinidin, peonidin, pelargonidin and 
petunidin––which differentiate on the basis of number and position of hydroxyl groups and degree of 
methylation [6]. 
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Figure 1. The flavan nucleus (1) is the basic structure of flavonoids, which include 
anthocyanidins (e.g., malvidin) (2), flavonols (e.g., quercetin) (3), flavones (e.g., luteolin) (4), 
flavanones (e.g., naringenin) (5), flavan-3-ols (e.g., epigallocatechin gallate) (6) and 
isoflavones (e.g., genistein) (7) differing in the level of oxidation and saturation of the C ring. 
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Oral cavity cancer is one of the most common and lethal head and neck malignancies. The overall 
incidence allows to consider these diseases the sixth more common form of cancer worldwide, with a 
high risk for recurrence (20%–30%) and a five-year survival rate of less than 50% [7,8]. Regional 
lymph node metastasis and loco-regional relapse are the main factors responsible for the poor survival 
rate of patients [7,8]. Even if head and neck cancers generally develop in the larynx and pharynx, they 
are intraoral in approximately 48% of cases, with a predominant location on the ventral/lateral lingual 
site or on the floor of the mouth. Less often, they can afflict others oral structures (gingiva and alveolar 
ridge, buccal mucosa, labial mucosa and hard palate). More than 90% of these cancers are classified 
histologically as oral squamous cell carcinoma (OSCC) [7,8]. 
Oral carcinogenesis is a highly complex, multifactorial process. The most important risk factors 
contributing to the etiology of oral cancer in Western countries are tobacco smoking and alcohol 
consumption [9]. Although drinking and smoking are independent risk factors, they have a synergistic 
effect, increasing the risk together [9]. Another relevant predisposing factor includes the presence of 
premalignant lesions associated to different degree of epithelial dysplasia [10]. Leukoplakia, 
proliferative verrucous leukoplakia, erythroplakia, erythroleukoplakia, oral submucous fibrosis and 
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oral lichen planus display, to different extents, a certain propensity for tissutal transformation to 
OSCC. Moreover, viral infections and genetics may further contribute to carcinogenesis [10]. In 
particular, human papillomavirus (HPV) infection, mainly related to type 16, has been recently 
suggested to play a role in oral cancer development [11–13]. Finally, individuals that carry the  
fast-metabolizing alcohol dehydrogenase type 3 (ADH3) allele may be particularly vulnerable to the 
effect of chronic alcohol consumption, and they could be at increased risk to develop oral cancer [9,10]. 
2. Oral Cancer Chemoprevention and Preclinical Evidence 
The transformation of a normal cell to cancer cell occurs through three distinct phases: initiation, 
promotion and progression. Initiation of cancer is due to the exposure of normal cells to carcinogenic 
and mutagenic agents. Initiated cells are irreversibly altered, and they are at higher risk of neoplastic 
transformation. However, initiation alone is not sufficient for tumorigenesis. In the promotion phase, 
cancer promoters convert the initiated cells into preneoplastic cells. Progression involves a stepwise 
evolution of preneoplastic cells into neoplastic cells with a higher degree of malignancy. Then, the 
tumoral mass acquires an aggressive characteristic, such as invasion and metastasis. 
In general, chemoprevention consists of the use of chemicals for reversal, suppression or prevention 
of the transformation of premalignant cells to a malignant geno/phenotype. Therefore, 
chemopreventive agents are classified into two categories: 
1. blocking agents prevent carcinogens from reaching and reacting with critical cell target sites, i.e., 
they prevent metabolic activation of carcinogens and stimulate their detoxification [14]; 
2. suppressing agents may impair the neoplastic transformation in target cells, at both early and late 
stages of carcinogenesis [14]. 
So far, the potential of flavonoids on oral health and as cancer chemopreventive agents has been 
demonstrated in many preclinical studies [15,16]. Indeed, with regard to oral cancer, many flavonoids 
have been investigated in vitro and in vivo. Two isoflavones, genistein and biochanin A, decreased the 
cell growth of OSCC cell lines with an IC50 of 50 µM and inhibited phosphorylation of ERK 
(extracellular signal-regulated kinase) and Akt, a mitogen-activated protein kinase (MAPK) and  
a serine/threonine protein kinase, respectively, involved in oral cancer proliferation [17]. The  
flavone baicalein induced G1 phase arrest in oral cancer cells by enhancing the degradation of  
CDK4 (cyclin-dependent kinase) and cyclin D1, and activating AhR (aryl hydrocarbon receptor) [18]. 
Similarly, quercetin (a flavonol) inhibited OSCC cell proliferation via both G1 phase arrest and 
mitochondria-mediated apoptosis, besides decreasing cell migration and invasion [19]. A  
p53-dependent apoptotic pathway induced by vitexin (a flavone) was also demonstrated in oral cancer 
cell [20]. In 7,12-dimethylbenz(a)anthracene (DMBA)-induced experimental oral carcinogenesis in 
Syrian hamsters, administration of the flavone apigenin prevented the formation of oral tumors, by 
reducing oxidative stress and modulating the phase I and phase II detoxification cascade responsible 
for xenobiotic biotransformation [21,22]. 
However, EGCG and other flavanols from Camellia sinensis L. are the most investigated flavonoids 
in oral cancer chemoprevention. Recently, excellent reviews have reported the cytotoxic activity of 
these compounds on different OSCC cell lines and in both chemical-induced and xenograft models of 
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OSCC in rodents, also investigating the molecular mechanisms involved in chemoprevention [23–25]. 
In particular, in vitro effects of EGCG on oral cancer cells included three main steps: (i) inhibition of 
cell proliferation via apoptosis induction and cell cycle arrest; (ii) modulation of transcription factors, 
namely nuclear factor-κB (NF-κB) and activator protein (AP)-1; (iii) and reduction of cell migration 
and invasion by decreasing the production of matrix metalloproteinases. In different animal models of 
oral carcinogensis, tea polyphenols reduced oxidative stress and phase I enzymes while inducing phase 
II enzyme activities [23,24]. On the basis of preclinical evidence, clinical trials have been recently 
conducted, thus, in the next section, we will briefly deal with human studies on the chemopreventive 
potential of flavonoids, mainly focusing of EGCG and green tea. 
3. Epidemiological Studies 
One of the first studies correlating increased oral cancer risk to low intake of fruits and vegetables––rich 
in flavonoids––was published three decades ago. Increased consumption of fruits and vegetables was 
shown to be protective against oral cancer, when statistically controlled for demographic traits, tobacco 
and alcohol use, relative weight and intake of other food items [26]. More recently, high fruit and 
vegetable intake was associate with reduced risk of head and neck cancer, in a pooled analysis by the 
INHANCE (International Head and Neck Cancer Epidemiology) consortium which collected data from 
22 case-control studies with 14,520 cases and 22,737 controls. Interestingly, red and processed meat 
intake was positively associated with increased risk of head and neck cancer [27]. 
The consumption of flavonoids has been inversely correlated to the risk of oral cancer in two  
case-control studies conducted in Uruguay and Italy, which reported relative risks (RRs) for the 
highest level of flavonoid intake of 0.8 and 0.56, respectively [28,29]. In particular, in the Italian study, 
a significant inverse association was found for flavanones, flavonols and total flavonoids, with odds 
ratios (ORs) for the highest versus the lowest quintile of intake of 0.51, 0.62 and 0.56, respectively. No 
significant association emerged for other classes of flavonoids, i.e., isoflavones (OR, 0.90), 
anthocyanidins (OR, 0.86), flavan-3-ols (OR, 0.84) and flavones (OR, 0.75) [29]. 
The association between green tea consumption and oral cancer risk was studied in the Japanese 
Collaborative Cohort Study. A total of 20,550 men and 29,671 women aged 40–79 years without any 
history of oral cancer were included at baseline in this prospective study. During a mean follow-up 
period of 10.3 years, 37 oral cancer cases were identified. For women, the hazard ratios (HRs) of oral 
cancer for a green tea consumption of 1–2, 3–4 or 5 cups/day were 0.51, 0.60 and 0.31, respectively, 
compared to 1 cup/day. For men, the inverse association was slightly lower, and, in any case, it did not 
reach statistical significance due to the relatively low number of cancer cases included in the analysis [30]. 
Tea intake was not associated with oral cancer in the Cancer Prevention Study II, a large 
prospective US cohort study that began in 1982, involving 968,432 men and women, cancer-free at 
enrolment [31]. However, in this study, the type of tea consumed––black or green—was not specified. 
Whereas catechins are found in green tea, the main constituents of black tea are theaflavins and 
thearubigins, which are formed by the oxidation and polimerization of catechins during fermentation 
and, presumably, possess different biological activities [32]. 
Conversely, in the French ICARE (Investigation of Occupational and Environmental Causes of 
Respiratory Cancers) study, a large multicenter, population-based, case-control study on lung and 
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upper aerodigestive tract cancers was carried out from 2001 to 2007 in 10 French administrative areas, 
an inverse association between oral cavity cancer and tea and/or coffee intake was observed. For the 
highest quartile of exclusive tea or coffee consumption, ORs were 0.39 and 0.60, respectively, with a 
synergistic effect when both consumed by the same subject. No difference in risk between men and 
women was reported [33]. 
Finally, according to a meta-analysis by the Cochrane Collaboration of 51 studies including more 
than 1.6 million participants, evidence that the consumption of green tea may reduce the risk of cancer 
is conflicting. Drinking green tea remains unproven in oral cancer prevention, but appears to be safe 
for moderate, regular, and habitual use [34]. 
4. Clinical Studies 
To the best of our knowledge, tea catechins are the only flavonoids investigated in clinical studies 
on oral cancer. The first clinical trial using green tea for treatment of an oral premalignant lesion was a 
double-blind, placebo-controlled, randomized, phase II clinical trial in 59 patients with oral mucosa 
leukoplakia receiving either 3 g/day of a mixed tea product in oral capsules, in four divided doses, plus 
10% mixed tea ointment in glycerine topically, or placebo plus topical glycerine. Applying the tea 
extract directly to the lesions may improve the local concentrations of the active constituents. The 
mixed tea was composed of a dried mixture of water-soluble green tea extract, green tea polyphenols 
and tea pigments (theaflavins and thearubigins). After six months of intervention, the size of oral 
lesions decreased in 37.9% and increased in 3.4% of the 29 tea-treated patients, whereas they 
decreased in 10.0% and increased in 6.7% of the 30 subjects in the placebo group [35]. 
Administration of a green tea extract (2000–2500 mg/day) to smokers for four weeks reduced DNA 
damage in oral keratinocytes. Moreover, cell growth was also inhibited, the percentage of cells in S 
phase decreased, cells accumulated in G1 phase, DNA content became more diploid and less 
aneuploid, and apoptotic markers were upregulated [36]. 
Another randomized, placebo-controlled, phase II trial evaluated the chemopreventive potential of 
green tea extract on oral cancer. The effects of administration of green tea capsules containing 13.2% of 
EGCG (26.9% of catechins) were examined on 41 patients with one or more histologically confirmed, 
bidimensionally measurable oral premalignant lesions at high risk of malignant transformation. Patients 
were randomized to receive green tea extract at 1.0 g/m
2
 (n = 10), 0.75 g/m
2
 (n = 9), 0.5 g/m
2
 (n = 11) or 
placebo, three times daily for 12 weeks. The efficacy was determined by the disappearance of all 
lesions (a complete response) or 50% or higher decrease in the sum of diameters of all measured 
lesions (a partial response). The authors found that the two high-dose arms (0.75 and 1.0 g/m
2
) 
revealed higher clinical response rates (58.8%) than 0.5 g/m
2
 (36.4%) or placebo (18.2%), even if rates 
did not reach statistical significance, suggesting a dose-response effect of green tea extract. The latter 
was well tolerated, with only insomnia (with higher doses, possibly due to the caffeine present in the 
extract), diarrhea and oral/neck pain. At a median follow-up of 27.5 months, there was no difference in 
oral cancer-free survival between the green tea extract arm and the placebo arm [37]. Finally, in 
patients with oral field cancerization, at a high risk for developing recurrent oral precancerous and 
cancer lesions, application of EGCG in a form of mouthwash for seven days decreased the expression 
levels of some biomarkers of oral carcinogenesis, though not statistically significant. It is noteworthy 
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that detectable levels of EGCG were measured in saliva, but not in plasma, thus demonstrating local 
bioavailability of this catechin in oral mucosa without significant systemic absorption [38]. 
5. Oral Bioavailability of Flavonoids 
Studying the biological activity of phytochemicals in humans, the knowledge of their 
pharmacokinetic and bioavailability is crucial. For food bioactive components, oral bioavailability is 
defined as the fraction of substances, obtained from ingested foods, that reach systemic circulation for 
further delivery to target tissues and organs, where they subsequently exert their biological activities. 
Flavonoids are recognized as xenobiotics by the human body. Consequently, to produce beneficial 
effects after ingestion, they have to be absorbed and metabolized before being delivered to target 
tissues and organs by the bloodstream [32,39]. Though biological activities of flavonoids have been 
demonstrated in many preclinical models, the effective concentrations in vitro (sub- to low-micromolar 
levels) are at least one order of magnitude higher than those normally measured in human plasma (tens 
to hundreds of nanomolar) [40]. To amount to effective concentrations at their sites of action, ingested 
flavonoids have to overcome a number of barriers represented by the complex structures of the 
gastrointestinal tract [41]. In general, the bioavailability of dietary flavonoids is not only limited by 
their physicochemical properties, but also because of active efflux by multidrug resistance-associated 
proteins or extensive biotransformation by phase I and phase II enzymes, including the first-pass 
hepatic metabolism, and gut microbiota [32]. In particular, the dietary forms of flavonoids, flavonoid 
glycosides, are considered inactive; they thus have to first be hydrolyzed to their active aglycones at 
enteric level. Significantly, hydrolysis of quercetin and genistein glucosides to their aglycones has 
been reported in human oral cavity, i.e., in saliva and epithelial cells, due to both bacterial and 
epithelial β-glucosidases. Interestingly, hydrolysis was limited to glucose conjugates: other glycosides 
either were hydrolyzed very slow or were resistant to salivary hydrolysis. A remarkable inter-individual 
variability in hydrolysis rate was thus observed. Cytotoxicity of quercetin and genistein was also 
demonstrated in vitro on oral cancer cells, thereby suggesting that the aglycones formed in the oral 
cavity may exert anticancer activity [42]. More recently, intraoral bioactivation of anthocyanins via 
microbial, salivary and epithelial β-glucosidases has been described, with a high inter-individual 
variability. The authors also reported that, comparable to small intestine, the hydrolytic, phase II and 
efflux transporting enzymes necessary for local enteric recycling are present and functional in human 
oral mucosa [43]. Glucuronidated phase II anthocyanin conjugates were also detected in saliva [43]. 
6. Future Perspectives: Nanoparticles and Oral Transmucosal Delivery to Improve Systemic and 
Local Bioavailability 
Poor bioavailability is the major drawback associated with the failure of many natural 
chemopreventive agents in clinical settings. In fact, despite the promising data obtained by 
chemoprevention by bioactive plant food components in preclinical studies, fallout of these results to 
humans showed limited success, possibly because of inefficient systemic delivery and low 
bioavailability of these promising chemopreventive agents. To date, a novel approach based on the use 
of nanotechnology to improve the outcome of cancer chemoprevention was developed, and a new 
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concept termed ―nanochemoprevention‖ was introduced, referring to encapsulation of 
chemopreventive agents in biocompatible nanoparticles [44,45]. 
Encapsulated EGCG in polylactic acid-polyethylene glycol nanoparticles retained its biological 
activity with over 10-fold dose advantage. In vitro, nano-EGCG was more cytotoxic to human prostate 
carcinoma PC3 cell lines, resulting in enhanced cellular apoptosis and inhibiting angiogenesis than  
non-encapsulated EGCG. A higher anticancer activity of the nanoformulation was also demonstrated 
in xenografted athymic nude mice [46]. 
Chemopreventive efficacy of naringenin-loaded nanoparticles was described in DMBA-induced 
experimental oral carcinogenesis in Syrian hamsters. Oral administration of naringenin-loaded 
nanoparticles completely prevented tumor formation as compared to free naringenin, and significantly 
reduced the degree of histological lesions. Additionally, in the buccal mucosa of DMBA-exposed 
animals, nanoparticles downregulated the expression of PCNA (proliferating cell nuclear antigen) and 
p53, and exerted higher anti-lipid peroxidative and antioxidant activities, when compared with free 
naringenin [47]. 
To benefit from flavonoid healthy effects, the local exposition of oral cavity to these compounds 
appears to be pivotal. In these terms, buccal and sublingual drug delivery technologies represent 
another promising and challenging approach. The transmucosal oral route is a method of systemic drug 
delivery that offers several advantages over gastro-enteric and parenteral routes. Oral mucosa is 
composed of three portions, from the top to the bottom: (a) an outermost layer of pluri-stratified 
squamous epithelium, with different degrees of cheratinization according to the oral site considered, 
for instance hard palate mucosa or gingival mucosa are more cheratinized than buccal mucosa; the 
basal epithelial layer is placed on (b) a basement membrane, consisting of collagen, laminin and 
fibronectin, in turn directly lying on (c) lamina propria or submucosa, as the innermost layer, 
comprised of connective tissue. Therefore, it represents a highly permeable and vascularized tissue 
which provides a rapid drug transport to systemic circulation, avoiding degradation by first-pass 
hepatic metabolism and pre-systemic elimination within the gastrointestinal tract. Furthermore, in 
comparison to intravenous and intramuscular administrations, transmucosal oral drug absorption is 
non-invasive, more comfortable and acceptable by patients. Buccal and sublingual delivery systems 
use mouthwashes, aerosol sprays, chewing gums, bioadhesive tablets, gels and patches to locally treat 
conditions such as gingivitis, oral candidosis, oral lesions, dental caries and xerostomia [48,49]. 
Although many drugs have been formulated for transmucosal oral delivery in order to treat both  
local and systemic conditions, only very few studies have been carried out on flavonoid and oral 
cancer [50,51]. 
Topical application to a selected mucosal site (posterior mandibular gingival mucosa) of a 
bioadhesive gel rich in anthocianins, containing 10% (w/w) black raspberry, produced detectable 
salivary and tissutal levels of black raspberry anthocyanins in healthy volunteers, and confirmed that 
gel-delivered flavonoids are readily released in the salivary environment and easily penetrate oral 
mucosa [52]. Similarly, in healthy volunteers, intraoral application of the same gel raised the levels of 
anthocyanins not only in saliva and oral tissues, but also in plasma samples [53]. Black raspberry gel 
was topically applied four times daily for six weeks to 17 patients with oral intraepithelial neoplasia, 
and pre- and post-treatment biopsies were evaluated. Seven patients showed histopathological 
improvement, six exhibited stable disease, and four evidence of progression. Then, the authors 
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investigated the association between loss of heterozygosity and histological tissue modification, since 
loss of heterozygosity is associated with the development of many human cancers, including OSCC. A 
reduction in loss of heterozygosity at tumor suppressor gene-associated loci was observed: the study, 
thus reported a weak association between reduction in loss of heterozygosity and improvement in 
histopathology grade [54]. Finally, the same authors demonstrated that, in patients with oral 
premalignant lesions, topical berry gel application modulated the expression profile of oral 
intraepithelial neoplastic genes, suppressing those involved in RNA processing, growth factor 
recycling and inhibition of apoptosis. Treatment also reduced epithelial COX (cyclooxygenase)-2 
protein, vascular density in the superficial connective tissues and genes associated with keratinocyte 
differentiation [55]. 
7. Conclusions 
At the end of this brief survey, we can summarize that the current evidence of human oral cancer 
chemoprevention by flavonoids is still fragmentary and inconclusive, yet nonetheless promising, as 
suggested by both epidemiological and preclinical studies. It is noteworthy that the anticancer activity 
of these phytochemicals has been extensively reported. 
Promising results have been recorded for EGCG and anthocyanins from green tea and black 
raspberries, respectively, though still inconsistent. Further studies, conducted following an evidence-based 
approach, are needed. In particular, phase III clinical trials with a high number of patients are required 
to confirm the efficacy of flavonoids on oral cancer prevention, as well as studies able to clarify the 
mechanisms involved in chemoprevention. Significantly, emerging technologies may maximize  
the chemopreventive potential of flavonoids, such as functionalization with nanoparticles and  
oro-transmucosal delivery, enhancing the efficacy of these phytoconstituents and improving their local 
and systemic bioavailability, the foremost weak point of nutritional therapy. 
In perspective, the major outcome of these studies will be to increasingly figure out the relation of 
causality between phytochemicals and oral cancer prevention and/or treatment, thereby minimizing 
casuality. Indeed, benefits may be further enhanced by other ―health-promoting‖ confounding factors, 
such as physical activity and other lifestyles associated to wellbeing conditions. 
Finally, we have to take into account that, depending on dietary habits, we are exposed daily to 
hundreds of bioactive phytochemicals present in whole foods. Therefore, the additive and synergistic 
effects of all components, identifiable in fruits and vegetables, are more realistically responsible for the 
health-promoting properties ascribed to these foods, even if in vitro/in vivo studies mainly focused on 
the specific biological activities of only a few plant metabolites. 
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